Gastrointestinal Cancer News

The FDA granted priority review to iobenguane I 131 for the treatment of patients with malignant, recurrent or unresectable pheochromocytoma and paraganglioma, according to the agent’s manufacturer.

Surveillance for hepatobiliary cancers with imaging modality significantly improved outcomes and overall survival in patients with primary sclerosing cholangitis, according to recently published data.

Five ASCO members have been elected to the society’s board of directors to fill existing vacancies.

Howard A. “Skip” Burris III, MD, FACP, FASCO, has been elected to serve as president of ASCO for the 2019-2020 term.

The top stories in hematology and oncology this year included articles on study results published in peer-reviewed journals, FDA approvals and practice-changing data presented at scientific meetings, as well as articles that featured interviews with leading researchers and expert opinions on approaches to patient care.

Portal hypertension did not negatively affect survival rates in patients who underwent liver resection for hepatocellular carcinoma, according to recently published data. While multiple tumors did affect survival, researchers considered the survival benefit from liver resection in these patients to be acceptable.

Only two of 23 indications for six FDA-approved immuno-oncology agents showed durable survival benefits under the revised ASCO value framework, according to study findings.

This case involves a 60-year-old female smoker who presented with ear discomfort.

J. William Charboneau, M D, received the 2017 Gold Medal from the Radiological Society of North America.

Elevated postoperative serum carcinoembryonic antigen increased risk for recurrence, especially within the first 12 months after surgery, among patients with colon adenocarcinoma, according to a retrospective cohort analysis published in JAMA Oncology.